---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-343482"
form_type: "8-K"
ticker: "MREO"
cik: "0001719714"
company_name: "Mereo BioPharma Group plc"
filed_at: "2026-08-11T12:07:21+00:00"
generated_at: "2026-08-11T12:10:18.195479+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Mereo, Sentynl sign option/license deal for alvelestat in AATD-LD; up to $40M upfront, $435M milestones

## Summary
- Non-refundable option fee; on exercise $40M upfront/R&D, up to $435M milestones, double-digit tiered royalties on US sales.
- Sentynl gets US commercial and global manufacturing rights; Mereo keeps rest-of-world rights and leads global Phase 3.
- Alvelestat is a neutrophil elastase inhibitor; potential first oral treatment for AATD-LD affecting ~50k-80k US patients.
- Phase 3 could start early 2027; backed by positive efficacy data from two Phase 2 studies.
- Agreement dated Aug 11, 2026; parties to collaborate on manufacturing and Phase 3 design during option period.

## SEC filing metadata
- accession: 0001193125-26-343482
- form_type: 8-K
- ticker: MREO
- cik: 0001719714
- company_name: Mereo BioPharma Group plc
- filed_at: 2026-08-11T12:07:21+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719714/000119312526343482/0001193125-26-343482-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719714/000119312526343482/mreo-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-343482
- JSON: https://secwatch.observer/filing/0001193125-26-343482.json
- Plain text: https://secwatch.observer/filing/0001193125-26-343482.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.